Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06523465 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Statin Combined with Amlodipine Treats Primary Aldosteronism

Study acronym: STOP-PA
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 22, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Study completion date: Jul 30, 2026 to Sep 30, 2026
    • Start date changed from estimate of Sep 1, 2024 to Sep 10, 2024
    v3
  2. Start date: Aug 1, 2024 to Sep 1, 2024
    • Enrollment target: 150 to 180
    • Interventions: Amlodipine besylate combined Spironolactone (Drug), Atorvastatin combined with Amlodipine besylate (Drug), Atorvastatin combined with… to Amlodipine besylate combined Spironolactone (Drug), Simvastatin combined with Amlodipine besylate (Drug), Simvastatin combined with…
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.
Trial Details
NCT Number NCT06523465
Lead Sponsor Third Military Medical University
Conditions
(from sponsor)		 Primary Aldosteronism, Statin, Mineralocorticoid Receptor Antagonist, Hypertension
Related terms Hyperaldosteronism, Hypertension
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov